10x Genomics Inc.
15.42
-0.29 (-1.85%)
At close: Jan 14, 2025, 3:59 PM
15.44
0.13%
Pre-market Jan 15, 2025, 04:09 AM EST
undefined%
Bid 15.26
Market Cap 1.87B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.52
PE Ratio (ttm) -10.14
Forward PE n/a
Analyst Buy
Ask 16.25
Volume 1,633,554
Avg. Volume (20D) 1,906,465
Open 15.89
Previous Close 15.71
Day's Range 15.06 - 16.47
52-Week Range 12.95 - 51.22
Beta undefined

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene...

Sector Healthcare
IPO Date Sep 12, 2019
Employees 1,259
Stock Exchange NASDAQ
Ticker Symbol TXG

Analyst Forecast

According to 16 analyst ratings, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 58.88% from the latest price.

Buy 50.00%
Hold 43.75%
Sell 6.25%
Stock Forecasts

Next Earnings Release

10x Genomics Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $153.51M, reflecting a -16.56% YoY shrinking and earnings per share of -0.15, making a -37.50% decrease YoY.
3 months ago · Source
-24.7%
10x Genomics shares are trading lower after the co... Unlock content with Pro Subscription
3 months ago · Source
+3.48%
10x Genomics shares are trading lower after the company guided Q3 preliminary revenue of ~$151.7 million, down 1% year over year.